Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
Jordi Rodón, Guillem Argilés, Roisín M. Connolly, Ulka N. Vaishampayan, Maja J.A. de Jonge, Elena Garralda, Marios Giannakis, David C. Smith, Jason R. Dobson, Margaret E. McLaughlin, Abdelkader Seroutou, Yan Ji, Jennifer Morawiak, Susan E. Moody, Filip Jankú
Topics & Concepts
DysgeusiaAXIN2MedicineAdverse effectInternal medicineBiomarkerDurvalumabMaximum tolerated doseOncologyPharmacologyWnt signaling pathwayPathologyImmunotherapyCancerBiologyPembrolizumabGeneBiochemistryWnt/β-catenin signaling in development and cancerSkin and Cellular Biology ResearchImmunotherapy and Immune Responses